Drug Trial Radar · NCT07376629
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
60
Planned (sponsor's estimate)
Start
Aug 14, 2025
Primary completion
Jan 15, 2027
Study completion Jan 15, 2027
Sponsor
- Lead sponsor
- Huabo Biopharm Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of HB0025 administered with chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
Conditions
- TNBC
Interventions
HB0025 20 mg/kg plus nab-paclitaxelDrug
HB0025 20 mg/kg
HB0025 10 mg/kg plus nab-paclitaxelDrug
HB0025 10 mg/kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- The safety and tolerability measures: Incidence,correlation, and severity of adverse events graded according to NCI CTCAE v5.0.Time frame: From first dose to the time of the disease progression, intolerable toxicity, initiation of new antitumor therapy, loss to follow-up, death, withdrawal of study, completion of 2-year treatment of HB0025, or other reasons, whichever comes first.
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Anyang Cancer Hospital
Anyang, China
Xiangya Hospital Central South University
Changsha, China
Sichuan Cancer Hospital
Chengdu, China
Fujian Cancer Hospital
Fujian, China
Guangdong Provincial People's Hospital
Guangdong, China
Sun Yat-sen University Cancer Center
Guangzhou, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Anhui Provincial Hospital
Hefei, China
The First Hospital of Jilin University
Jilin City, China
Affiliated Hospital of Jining Medical University
Jining, China
Linyi Cancer Hospital
Linyi, China
Jiangsu Province Hospital
Nanjing, China
Shandong Cancer Hospital
Shandong, China
Fudan University Shanghai Cancer Center
Shanghai, China
Shanxi Cancer Hospital
Shanxi, China
Liaoning Cancer Hospital
Shengyang, China
The Second Affiliated Hospital of Soochow University
Suzhou, China
Tianjin Cancer Hospital
Tianjing, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
The First Affiliated Hospital of Xiamen University
Xiamen, China
Xuzhou Central Hospital
Xuzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.